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Calcium ions (Ca2+) play a complex role in orchestrating diverse cellular processes, 
including cell death and survival. To trigger signaling cascades, intracellular Ca2+ is shuf-
fled between the cytoplasm and the major Ca2+ stores, the endoplasmic reticulum (ER), 
the mitochondria, and the lysosomes. A key role in the control of Ca2+ signals is attributed 
to the inositol 1,4,5-trisphosphate (IP3) receptors (IP3Rs), the main Ca2+-release channels 
in the ER. IP3Rs can transfer Ca2+ to the mitochondria, thereby not only stimulating 
core metabolic pathways but also increasing apoptosis sensitivity and inhibiting basal 
autophagy. On the other hand, IP3-induced Ca2+ release enhances autophagy flux by 
providing cytosolic Ca2+ required to execute autophagy upon various cellular stresses, 
including nutrient starvation, chemical mechanistic target of rapamycin inhibition, or drug 
treatment. Similarly, IP3Rs are able to amplify Ca2+ signals from the lysosomes and, there-
fore, impact autophagic flux in response to lysosomal channels activation. Furthermore, 
indirect modulation of Ca2+ release through IP3Rs may also be achieved by controlling 
the sarco/endoplasmic reticulum Ca2+ ATPases Ca2+ pumps of the ER. Considering 
the complex role of autophagy in cancer development and progression as well as in 
response to anticancer therapies, it becomes clear that it is important to fully understand 
the role of the IP3R and its cellular context in this disease. In cancer cells addicted to 
ER–mitochondrial Ca2+ fueling, IP3R inhibition leads to cancer cell death via mechanisms 
involving enhanced autophagy or mitotic catastrophe. Moreover, IP3Rs are the targets 
of several oncogenes and tumor suppressors and the functional loss of these genes, as 
occurring in many cancer types, can result in modified Ca2+ transport to the mitochondria 
and in modulation of the level of autophagic flux. Similarly, IP3R-mediated upregulation of 
autophagy can protect some cancer cells against natural killer cells-induced killing. The 
involvement of IP3Rs in the regulation of both autophagy and apoptosis, therefore, directly 
impact cancer cell biology and contribute to the molecular basis of tumor pathology.
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iNTRACeLLULAR Ca2+ SiGNALiNG: THe eNDOPLASMiC 
ReTiCULUM (eR), MiTOCHONDRiA, AND LYSOSOMeS
Intracellular Ca2+ signaling controls a plethora of cellular processes, including secretion, gene 
transcription, metabolism, and cell death, thereby impacting cell function and cell survival (1–3). 
Intracellular Ca2+ signals are characterized by their spatiotemporal properties. As a function of 
time, Ca2+ signals can occur as transient increases in [Ca2+] (Ca2+ oscillations) (4) or as more 
2Kania et al. IP3Rs and Autophagy in Cancer
Frontiers in Oncology | www.frontiersin.org July 2017 | Volume 7 | Article 140
sustained increases in [Ca2+] (global Ca2+ transients) (5). As a 
function of space, Ca2+ signals can occur in localized domains 
near the plasma membrane (PM) or organelles, such as the ER, 
mitochondria, lysosomes, Golgi, and nucleus (3, 6). Localized 
Ca2+ signaling is established in so-called microdomains due to 
the close apposition of different organellar compartments (7–9) 
or of organelles with the PM through molecular tethers (10–12).
The major intracellular Ca2+-storage organelle is the ER, 
where most of the intracellular Ca2+ is accumulated via active 
Ca2+ transport mediated by sarco/endoplasmic reticulum Ca2+ 
ATPases (SERCA) followed by intraluminal Ca2+ buffering by 
calreticulin, calnexin, and other Ca2+-binding proteins (13, 14). 
These mechanisms allow for an adequate Ca2+ filling of the ER, 
which is required for the activity of molecular chaperones and the 
folding of enzymes. Hence, a depletion of the ER Ca2+ stores leads 
to ER stress, a condition associated with impaired protein folding 
capacity (13, 15, 16). To cope with this, cells engage the unfolded 
protein response, a concerted program triggered through the 
three classical ER stress sensors: inositol-requiring enzyme1α, 
RNA-dependent protein kinase-like ER kinase, and activating 
transcription factor 6 (17). Mild or transient ER stress induces 
activity of chaperones, folding enzymes, reactive oxygen species 
(ROS) scavengers, and degradative pathways, such as autophagy, 
while severe or persistent ER stress induces cell death (18–20).
These Ca2+-uptake mechanisms are counteracted by, on the 
one hand, Ca2+-leak channels and, on the other hand, Ca2+-
release channels (21). Ca2+-leak channels establish a constitutive, 
passive Ca2+ leak from the ER, preventing ER Ca2+ overload that 
would result in cell death. Different ER Ca2+-leak channels have 
been identified, likely all contributing to this passive Ca2+ leak to 
some extent, although it is possible that some of these channels 
are restricted to certain cell types or systems (22–25). Presenilin 
2, Ca2+ release-activated Ca2+ channel protein 2 (Orai2) and ino-
sitol 1,4,5-trisphosphate (IP3) receptor (IP3R) isoform 1 (IP3R1) 
have been proposed as major ER Ca2+-leak channels, based on a 
systems biology approach using HeLa cells (26). However, the ER 
Ca2+-leak rates in wild-type HEK293 versus HEK293 cells lacking 
all three IP3R isoforms, directly measured by using a genetically 
encoded ER Ca2+ sensor, were very similar, indicating that at least 
in HEK cells and these experimental conditions, IP3R does not 
contribute in an important way to the passive Ca2+ leak from the 
ER (27). These Ca2+-leak channels impact the steady-state Ca2+ 
content of the ER, which determines the Ca2+ available for release 
upon agonist stimulation (28, 29). Ca2+ release from the ER occurs 
through IP3Rs (30, 31) or ryanodine receptors (RyRs) (32–34). 
IP3Rs are ubiquitously expressed and are activated in response 
to IP3, which is produced from phosphatidylinositol 4,5-bisphos-
phate (PIP2) upon hydrolysis mediated by phospholipase C (35). 
This typically happens in response to cellular stimulation with 
hormones, growth factors, neurotransmitters, or antibodies. 
However, it is clear that many cells even in basal, non-stimulated 
conditions, display a constitutively low level of IP3-mediated sign-
aling. The Ca2+ depletion of the ER, resulting from Ca2+ release, 
can trigger the activation of store-operated Ca2+ entry (SOCE) 
through stromal interaction molecule 1 (Stim1)-dependent acti-
vation of Ca2+ release-activated Ca2+ channel protein 1 (Orai1) 
channels (36–38).
Ca2+ release from the ER does not only result in a [Ca2+] rise 
in the cytosol but also leads to [Ca2+] increase in other organelles, 
including the mitochondria and the lysosomes (6, 39). This is 
due to contact sites between ER and mitochondria and between 
ER and lysosomes, decreasing the distance between these orga-
nelles and the ER (39–43). In addition to this, a highly negative 
potential of about −180 mV exists across the mitochondrial inner 
membrane, establishing a strong electrochemical driving force 
for Ca2+ uptake in the mitochondria (40). It is well known that 
IP3R-mediated Ca2+ release from the ER can “quasi-synaptically” 
transfer into the mitochondria (7, 44). This occurs via the so-
called mitochondria-associated ER membranes (MAMs) that also 
harbor the IP3R and the voltage-dependent anion channel type 1 
that permeates Ca2+ across the mitochondrial outer membrane 
(39, 41, 42). Once in the mitochondrial intermembrane space, 
Ca2+ is transported across the mitochondrial inner membrane 
via the mitochondrial Ca2+ uniporter (MCU) (45). The MCU 
has low inherent affinity for Ca2+ and is highly cooperative due 
to accessory proteins such as MICU1 (46). By comparison, Ca2+ 
uptake into the lysosomes is much less understood. Nevertheless, 
it is anticipated that a strong electrochemical gradient for H+ is 
present resulting from a low lysosomal pH (~4–5) which can be 
used for lysosomal Ca2+ accumulation via the lysosomal H+/Ca2+ 
exchanger (47, 48). Ca2+ can be released from these lysosomal 
Ca2+ stores via a variety of channels, including two-pore chan-
nels 1/2 (TPC1/2) and transient receptor potential superfamily 
channels such as TRPML1 (mucolipin1/MCOLN1)(47, 49–52). 
An important second messenger triggering lysosomal Ca2+ 
release through TPC1/2 is nicotinic acid adenine dinucleotide 
phosphate (NAADP) (53–55). TRPML1 present in endolysomal 
vesicles can be activated by phospholipids such as phosphati-
dylinositol 3,5-bisphosphate [PI(3,5)P2] (56, 57).
Ca2+ SiGNALiNG iN AUTOPHAGY
eR-Derived Ca2+ Signaling in Autophagy
It is well-established that Ca2+ signaling impacts autophagy 
initiation and progression (Figure 1). Ca2+ signaling modulates 
as well basal autophagic flux as mechanistic target of rapamycin 
(mTOR)-controlled autophagic flux, induced by nutrient starva-
tion or rapamycin (58–60). Moreover, compounds that directly 
affect Ca2+ signaling, including agonists, Ca2+ ionophores, and 
SERCA inhibitors that indirectly cause ER Ca2+-store depletion 
via the basal Ca2+ leak, can modulate the autophagic process 
(61). The ER, as the main intracellular Ca2+-storage organelle, 
has been implicated in controlling basal autophagy. This is related 
to Ca2+-dependent energizing of the mitochondria (62). Basal 
and constitutive Ca2+-release events from the ER, mediated by 
IP3R channels, have been involved in sustaining mitochondrial 
bioenergetics by driving NADH production and subsequent ATP 
synthesis by continuously providing Ca2+ to the mitochondria 
(62) (Figure 1). This is due to the presence of three mitochondrial 
Ca2+-dependent tricarboxylic acid (TCA) cycle enzymes, which 
activities are enhanced by mitochondrial Ca2+ (40). Abrogating 
these Ca2+ signals through pharmacological inhibition or genetic 
knock down of IP3Rs resulted in an increased autophagic flux 
FiGURe 1 | Ca2+ regulates different steps of autophagy. Extracellular Ca2+ can enter the cell via the TRPM2 channel, where it activates CaMKII that 
phosphorylates Beclin 1, promoting its binding to Bcl-2 and blocking autophagy initiation. Beclin 1 can also be scaffolded to the IP3R, which also limits autophagy 
promotion. IP3Rs are responsible for fueling mitochondria with Ca2+, which supports the tricarboxylic acid (TCA) cycle and the resulting ATP production. The 
presence of an adequate ATP/AMP ratio suppresses the AMP-activated kinase (AMPK)–mechanistic target of rapamycin (mTOR)–unc-51-like kinase 1 (ULK1) axis 
and thus autophagy induction. Autophagosome maturation can be inhibited by the TRPML3 channel mostly expressed in endosomes, while fusion of 
autophagosomes and lysosomes can be blocked by basal RyR activity. Ca2+ release through lysosomal nicotinic acid adenine dinucleotide phosphate (NAADP)-
activated TPC2 channels can be further amplified by Ca2+ release from IP3Rs resulting in stimulation of the CaMKKβ–AMPK pathway and autophagosome 
formation. Ca2+ release from the lysosomes can, however, affect lysosomal pH and so abrogate fusion of lysosomes with autophagosomes as well as the further 
lysosome-dependent degradation. TRPML1, another lysosomal channel, can be regulated by different factors, including lysosomal mTOR, PI(3,5)P2 or reactive 
oxygen species (ROS). Ca2+ released from TRPML1 activates calcineurin, which binds and dephosphorylates TFEB and promotes its nuclear translocation, where 
TFEB induces transcription of various autophagy-related and lysosomal biogenesis genes. Plain black arrows indicate activatory and inhibitory pathways; dashed 
arrows indicate intracellular movement.
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due to an increase in the activity of the AMP-activated kinase 
(AMPK), a positive regulator of autophagy (i) inhibiting 
mTOR and (ii) activating the unc-51-like kinase 1 (ULK1) 
complex (63). However, the increased basal autophagic flux trig-
gered upon IP3R inhibition appeared independent on mTOR 
(62) (Figure  1). Thus, IP3Rs exert an inhibitory role on basal 
autophagy, and consequently IP3R inhibition results in increased 
basal autophagy. An additional mechanism for this autophagy-
inhibitory role of IP3Rs has been attributed to its Beclin 
1-scaffolding function (64, 65). Beclin 1 regulates autophagy 
by forming a complex with the class III phosphatidylinositide 
3-kinase Vps34, thereby stimulating phagophore nucleation, an 
early step in the autophagy process (66–68). It has been shown 
that the IP3R, independently of its Ca2+-flux properties, could 
serve as a sink for Beclin 1 recruitment, reducing the availability 
of free Beclin 1 to drive autophagy (69) (Figure 1).
Besides IP3Rs, RyRs have also been implicated in autophagy. 
In hippocampal neuronal stem cells, insulin withdrawal resulted 
in the upregulation of the RyR3 isoform, which triggered cell 
death through increased autophagy. Activation of RyRs using 
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caffeine increased autophagic cell death, while their inhibition 
using dantrolene suppressed this process (70). However, more 
recently, RyRs, both endogenously expressed in skeletal muscle 
cell lines and in dissociated rat hippocampal neurons or ectopi-
cally expressed in HEK cells, have been implicated in inhibition 
of autophagic flux, particularly at the level of autophagosome/
lysosome fusion (Figure  1). RyR inhibition resulted in an 
increase of autophagic flux, independent of mTOR activity 
or of early autophagy regulators (71). This indicates that both 
IP3Rs and RyRs could suppress basal autophagy, but by acting at 
a different level: IP3Rs by suppressing autophagy at a proximal 
level by driving mitochondrial bioenergetics and thus decreasing 
AMPK activity, while RyRs block autophagy at a distal level by 
counteracting the fusion of autophagosomes and lysosomes.
In contrast to this, Ca2+ mobilization from the ER into 
the cytosol by itself can augment autophagic flux. Both physi-
ological agonists as well as chemicals, such as Ca2+ ionophores 
and SERCA inhibitors, that provoke [Ca2+] rises in the cytosol 
originating from the ER result in the activation of Ca2+/calmod-
ulin-dependent kinase kinase β (CaMKKβ) that is an upstream 
activator of AMPK and autophagy (72). In fact, mechanisms that 
limited cytosolic [Ca2+] rise induced by these agents also limited 
autophagy induction. As such, Bcl-2, a known negative regulator 
of autophagy, was proposed not only to limit autophagy by scaf-
folding Beclin 1 but also by reducing the ER Ca2+-store content, 
thus suppressing cytosolic [Ca2+] rises and the extent of CaMKKβ 
activation (Figure 1) (73).
In addition to this, cytosolic [Ca2+] rises can promote auto-
phagosome formation by recruiting the phosphatidylinositol 
3-phosphate [PI(3)P]-binding protein, encoded by autophagy-
related gene (Atg) 18 (WIPI1/WIPI2), to autophagosomal mem-
branes. Atg18, together with Atg16L and ULK1, are recruited to 
early autophagosomal structures and are critical for the formation of 
LC3-positive autophagosomes (74). Furthermore, the autophago-
somal recruitment of Atg18 was blocked by cytosolic Ca2+ chela-
tion. This mechanism allowed for an induction of autophagy by 
cytosolic [Ca2+] rise independently of AMPK activation or mTOR 
inhibition (75). However, apart from the autophagy-inducing 
properties of thapsigargin and Ca2+ ionophores, these agents 
have also been reported to suppress autophagosome biogenesis at 
steps in the autophagy pathway subsequently to WIPI1 punctae 
formation but preceding autophagosome closure (76). This may 
relate to the disturbance of critical Ca2+ fluxes from the ER during 
the distal steps in the autophagy process, including the closure of 
the autophagosomal vesicles.
Beyond these roles in modulating basal autophagy, the ER 
and more particular ER-derived Ca2+ signals mediated via IP3Rs 
have been involved in driving starvation- and rapamycin-induced 
autophagy (58, 59). Starvation and rapamycin are two triggers 
that induce autophagy through inhibition of mTOR, a negative 
regulator of autophagy. Starvation- and rapamycin-induced 
autophagy resulted in enhanced Ca2+ signaling from the ER 
through a mechanism that involved complex formation between 
IP3Rs and Beclin 1 and a subsequent direct IP3R sensitization by 
Beclin 1 (58) (Figure 1). In turn, cytosolic Ca2+ and IP3R activity 
were critical for cells to be able to increase their autophagic flux 
in response to nutrient starvation and rapamycin.
Resveratrol (RSV) is a polyphenol found in some food prod-
ucts and in red wine. Several health-promoting effects have been 
attributed to RSV, including longevity, anti-aging, and improved 
cardiovascular health (77, 78). These beneficial effects of RSV 
have been linked to its ability to induce autophagy. RSV induces 
autophagy in a pleiotropic manner via both mTOR-dependent 
and -independent mechanisms. RSV can activate the deacety-
lases sirtuins, a positive regulator of AMPK (79, 80). RSV can also 
directly inhibit mTOR by docking onto its ATP-binding pocket 
and thus competing with ATP. The inhibition of mTOR and 
the presence of ULK1 appeared to be critical for RSV-induced 
autophagy (81). However, RSV can also promote autophagy in 
a non-canonical manner, whereby RSV induces autophagosome 
formation independently of Beclin 1 or its binding partner Vps34 
(82, 83). Also, Ca2+ signaling has been implicated in RSV-induced 
autophagy (27). RSV can deplete the ER Ca2+ stores independently 
of the presence or absence of IP3Rs (27), which in part may be due 
to its inhibitory effect on mitochondrial ATP production, thereby 
suppressing SERCA-mediated ER Ca2+ uptake (84). Yet, although 
RSV triggered a Ca2+ leak from the ER independently of IP3Rs, 
the ability of RSV to induce autophagy was critically dependent 
on the presence of IP3Rs and on the availability of cytosolic Ca2+ 
(27). In this study, the inhibitory effect of RSV on mTOR activity 
was confirmed and did neither require cytosolic Ca2+ nor IP3R 
expression (27).
endolysosomal-Derived Ca2+ Signaling  
in Autophagy
A genetic analysis of mucolipidosis type IV (MLIV), a lysosomal 
storage disease associated with severe neurological deficien-
cies, implicated that mutations in TRPML1 play a role in 
autophagy deregulation (85). Fibroblasts derived from MLIV 
patients expressing mutant TRPML1 displayed an increased 
autophagosome formation accompanied with a delay in the 
fusion of autophagosomes with lysosomes. This was proposed 
to contribute to an accumulation of p62 and a defective removal 
of ubiquitinated proteins and/or defective mitochondria (85). 
Also, chaperone-mediated autophagy (CMA) was defective 
in MLIV fibroblasts, which could be attributed to TRPML1’s 
ability to bind and recruit Hsc70 and Hsp40 proteins, two 
components critical for CMA, and a subsequent reduction in 
lysosomal LAMP2A-protein levels. As a consequence, oxidized 
proteins may accumulate in the cytosol due to their impaired 
degradation via CMA (86). However, in these studies, the role 
of TRPML1 channel activity and lysosomal Ca2+ release was not 
addressed.
One of the first data linking TRPML-mediated Ca2+ release 
and the autophagy pathway was provided from overexpression 
studies using TRPML3/MCOLN3 (87). This channel is mainly 
present in early endosomal compartments, where pH is not as low 
as in lysosomes. These endosomal compartments may host more 
functional TPRML3 channels than lysosomes, as low pH appears 
to inactivate TRPML3-mediated Ca2+ flux. Overexpression of 
TRPML3/MCOLN3 not only resulted in severe changes in the 
endosomal pathway, including increased endosomal pH, but also 
in defective autophagosome maturation (87) (Figure 1).
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More recently, a direct role of lysosomal Ca2+ release through 
TRPML1 channels in upregulating autophagy upon mTOR 
inhibition has been elucidated (88). Nutrient starvation resulted 
in rapid peri-lysosomal [Ca2+] rises, in the close proximity of 
TRPML1 channels. These [Ca2+] rises were concentrated around 
lysosomes and could not be observed in the bulk cytosol. In turn, 
[Ca2+] rises resulted in the activation of the Ca2+/calmodulin-
dependent phosphatase calcineurin, which can dephosphorylate 
the transcription factor TFEB. As a consequence, upon nutrient 
starvation, calcineurin dephosphorylated TFEB at two residues 
(Ser142 and Ser211) regulating TFEB nuclear translocation, 
resulting in nuclear accumulation of TFEB and activation of 
genes necessary for autophagy and lysosomal biogenesis (88) 
(Figure 1).
TRPML1 itself is also regulated during nutrient starvation. 
TRPML1 and the hereby associated Ca2+ flux from the lys-
osomes became upregulated upon nutrient deprivation, which 
was accompanied by transcription of autophagy-regulating 
genes (89). TRPML1 upregulation also occurred in response to 
complete inhibition of the mTOR complex 1 by Torin-1, while 
this was not observed upon treatment with rapamycin, a partial, 
allosteric inhibitor of mTORC1. A critical role for TFEB was 
found in the upregulation of TRPML1. Both starvation and 
Torin-1 treatment were able to induce TFEB dephosphoryla-
tion and its nuclear translocation, while rapamycin failed to do 
this. A more direct link between TFEB activation and TRPML1 
upregulation was shown by overexpressing constitutively 
dephosphorylated and thus active TFEB in cells, which resulted 
in a functional upregulation of TRPML1 channels. The upregula-
tion of TRPML1 activity by TFEB could be partially attributed to 
an increase in mRNA and protein expression of the channel, but 
likely also involved post-translational modifications or upregula-
tion of TRPML1-interacting/modulating proteins. Moreover, a 
role of the lysosomal lipid PI(3,5)P2, a TRPML1-activating lipid 
which levels decrease upon nutrient starvation, was proposed as 
part of a compensatory mechanism that causes upregulation of 
TRPML1. At the functional level, TRPML1 activity was critical 
for the increase in lysosomal proteolytic activity induced by 
nutrient starvation (89).
Interestingly, TRPML1 activity is not only controlled by 
PI(3,5)P2 levels and via the TFEB transcription factor but also 
directly by mTOR (90). In nutrient-replete conditions, when 
mTOR was active and autophagy was suppressed, mTOR phos-
phorylated two serine residues in the C-terminal tail of TRPML1, 
resulting in TRPML1 channel inhibition. Upon mTOR inhibition 
by rapamycin, leading to autophagy induction, TRPML1 became 
dephosphorylated and active, resulting in lysosomal Ca2+ release. 
Moreover, rapamycin could induce Ca2+ release in cells express-
ing wild-type TRPML1 but not in cells expressing TRPML1 in 
which the two phosphorylable serine residues were mutated. 
Thus, loss of TRPML1 phosphorylation upon mTOR inhibition 
results in increased TRPML1 activity, driving autophagic flux 
(90). However, at this point, it is not clear which phosphatase is 
responsible for dephosphorylating the serine residues that are 
phosphorylated by the mTOR kinase.
Recently, it was shown that TRMPL1 can serve as a redox 
status sensor and can release Ca2+ upon stimulation by ROS or 
by mitochondrial uncouplers (91, 92). As a result of this Ca2+ 
release, also calcineurin-dependent TFEB activation and nuclear 
translocation occurred, which could be blocked by the ROS 
scavenger N-acetyl-cysteine (NAC), as well as by BAPTA-AM 
or synthetic TRPML1 inhibitors (ML-SIs). Since mitochondrial 
uncouplers failed to stimulate nuclear translocation of TFEB in 
TRPML1 knockout (KO) cells, this points out that TRPML1 is 
specifically required for ROS-induced activation of TFEB. By 
contrast, functional TRMPL1 was not required for TFEB nuclear 
translocation induced by mTOR inhibition through Torin-1 or 
nutrient starvation (91). In addition, ROS-induced autophagy 
and lysosome biogenesis could be impeded by NAC treatment as 
well as by ML-SIs or TRPML1 KO (91).
In contrast to TRPML1-mediated Ca2+ release from the lys-
osomes, thereby positively regulating autophagy, TPC2 has been 
implicated in the inhibition of autophagy (93). TPC2 channels 
are activated by NAADP. Overexpression of TPC2 resulted in 
the accumulation of autophagosomes, a phenomenon boosted 
by NAADP but antagonized by either the NAADP antagonist 
Ned19 or by knockdown (KD) of the essential autophagy gene 
Atg5. The effect of TPC2 on autophagosome accumulation could 
be attributed to an increase in lysosomal pH upon lysosomal Ca2+ 
release, which inhibits autophagy at the level of autophagosome–
lysosome fusion (Figure  1). Therefore, lysosomal acidification 
could suppress TPC2-induced autophagosome accumulation 
(93). Similar findings of TPC2 have been observed in astrocytes, 
where its overexpression resulted in an increase in Beclin 1 and 
LC3-II levels (94). The latter may also relate to the accumulation 
of autophagosomes.
Ca2+ influx from extracellular environment
Recently, oxidative stress has been implicated in autophagy 
inhibition through induction of melastatin-related transient 
receptor potential cation channel member 2 (TRPM2)-mediated 
Ca2+ influx (95). Ca2+ influx resulted in the activation of Ca2+/
calmodulin-dependent protein kinase II (CaMKII), which 
phosphorylated Beclin 1 at Ser295 and abolished its autophagy-
inducing properties. The mechanism involved a decrease in 
Vps34 complex formation with phospho-Beclin 1 and increased 
Bcl-2 binding of phospho-Beclin 1 (Figure 1). Consequently to 
autophagy inhibition, oxidative stress triggered cell death in cells 
expressing TRPM2, while TRPM2 KD resulted in upregulated 
autophagy as a survival pathway in these cells. In addition, 
TRPM2/CaMKII activation further increased ROS production 
and contributed to mitochondrial fragmentation and loss of 
mitochondrial potential (95, 96).
iP3Rs AND AUTOPHAGY iN CANCeR
iP3Rs in Cancer
IP3Rs control different hallmarks of cancer (97, 98). In particular, 
IP3Rs impact cell death and survival by mediating Ca2+ release 
from the ER and subsequently affecting mitochondria-regulated 
processes, including bioenergetics and apoptosis (99). Moreover, 
several IP3R isoforms can have distinct functions, dependent 
not only on their functional properties but also on their subcel-
lular localization (100). For instance, IP3R3 has been particularly 
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associated with pro-apoptotic Ca2+ flux from ER into mitochon-
dria due to its localization at ER–mitochondrial contact sites 
(101, 102). As such, depending on the isoform and localization 
of the IP3R that is modulated, opposite effects can occur. Enhanced 
basal IP3R activity outside the MAMs may cause an increased 
passive Ca2+ leak from the ER. As a consequence, ER Ca2+ stores 
become less filled whereby less Ca2+ becomes available to be 
delivered to the mitochondria upon cellular exposure to a toxic, 
pro-apoptotic stimulus. By contrast, enhanced IP3R activity at the 
MAMs can increase not only mitochondrial bioenergetics but 
also the likelihood for pro-apoptotic Ca2+ transfers. In addition, 
Ca2+ transfer into the mitochondria also participate in oncogene-
induced and replicative senescence, a stable proliferation arrest 
accompanied with distinct features like increased apoptosis 
resistance and altered gene expression (103–105). Here, IP3R2 
and MCU were implicated in the enhanced mitochondrial Ca2+ 
transfer and accumulation that resulted in cellular senescence 
due to a decline in mitochondrial membrane potential and an 
increased ROS production and senescence. Therefore, loss of 
ITPR2, the gene encoding IP3R2, or of MCU overcame the growth 
arrest and escape from senescence (105, 106).
IP3Rs emerged as functional targets of an increasing number 
of oncogenes and tumor suppressors, which dynamically control 
IP3R activity and thus Ca2+ flux from ER into mitochondria 
(97, 107). Several oncogenes can suppress pro-apoptotic Ca2+-
release events mediated by IP3Rs and this can occur via different 
mechanisms. First, oncogenes can directly interact with IP3Rs (97). 
For instance, anti-apoptotic Bcl-2 targets the central, modulatory 
domain of the IP3Rs, thereby suppressing excessive IP3R activity 
and protecting cells against pro-apoptotic Ca2+-release events 
(108–111). Alternatively, oncogenes can exert post-translational 
modifications of IP3Rs. Protein kinase B (PKB/Akt) phosphoryl-
ates IP3R3 and dampens its Ca2+ flux, suppressing pro-apoptotic 
Ca2+ transfer (112). Oncogenes not only prevent excessive 
IP3R-mediated Ca2+ release, but they can also promote basal 
Ca2+-signaling events that are associated with increased mitochon-
drial bioenergetics and, thus, increased NADH and ATP output. 
As such, Bcl-XL, another anti-apoptotic Bcl-2-family member 
sensitizes all IP3R isoforms, thereby promoting the occurrence of 
pro-survival Ca2+ oscillations and thus sustaining cell survival by 
boosting the mitochondrial metabolism (113–115).
Not only oncogenes but also tumor suppressors regulate IP3Rs 
(97, 107). The product of the BRCA1 gene, frequently mutated 
in breast cancer, binds and promotes IP3R activity. This under-
lies adequate apoptosis sensitivity of cells expressing wild-type 
BRCA1, while oncogenic mutations fail to engage IP3Rs and, thus, 
promote apoptosis resistance (116). Tumor suppressors can also 
act via post-translational modification of IP3Rs. As such, phos-
phatase and tensin homolog (PTEN) not only counteracts PKB/
Akt activity by reducing phosphatidylinositol 3,4,5-trisphosphate 
(PIP3) levels but also reverses the PKB/Akt-dependent phospho-
rylation of IP3Rs, particularly at the MAMs where IP3R3 becomes 
dephosphorylated and de-repressed (117).
In addition to these events, oncogenic mutations in cancer 
genes can also affect IP3R expression levels. As such, the expres-
sion of mutant Ras in cells resulted in an IP3R-isoform switch, 
thereby reducing the pro-apoptotic IP3R3 isoform and increasing 
the pro-survival IP3R1 isoform (118). IP3R1 displays a higher IP3 
sensitivity than IP3R3 and it is proposed to be less involved in pro-
apoptotic Ca2+ transfers from ER into mitochondria than IP3R3. 
The elevated IP3R1-expression levels resulted in an increased Ca2+ 
leak from the ER and thus a slight decrease in ER Ca2+ content, 
which reduced Ca2+ availability for pro-apoptotic Ca2+ transfer at 
the ER–mitochondrial contact sites (118).
Finally, oncogenes and tumor suppressors can affect ER Ca2+ 
homeostasis by modulating other ER Ca2+-transport systems. 
For instance, the tumor suppressor p53 accumulates at ER 
membranes, targeting and boosting SERCA in cells exposed to 
toxic, chemotherapeutic, and photodynamic agents (119, 120). 
As a consequence, ER Ca2+ stores became overfilled and the 
likelihood to flood mitochondria with excess Ca2+ increased, 
underlying cell death induction by these agents. Cancer cells 
lacking p53 or having mutated p53 failed to increase SERCA 
activity and, thus, did not display increased mitochondrial Ca2+ 
overload, which contributed to the resistance of these cells to 
these toxic agents (119, 120). Recently, in neuroblastoma cells, 
acute application of cisplatin, a DNA alkylating agent, and 
topotecan, a topoisomerase I inhibitor, resulted in a rapid Ca2+ 
release from the ER stores (121). In addition to this, long-term 
exposure of neuroblastoma to these drugs resulted in a remod-
eling of Ca2+-transport systems, including an upregulation of 
IP3R and RyR isoforms. Blocking Ca2+ release from the ER by 
inhibiting these channels or by chelating cytosolic Ca2+ using a 
cell-permeable Ca2+ buffer, suppressed cell death in neuroblas-
toma treated with cisplatin and topotecan (121). For a detailed 
discussion on the impact of oncogenes and tumor suppressors 
on ER Ca2+ signaling and IP3R more specifically, we would like 
to refer to other recent reviews dedicated to this topic (107, 122).
In addition to this, altered IP3R expression has been implicated 
in a variety of cancer-associated processes. For instance, a subset 
of tumor tissue samples derived from breast cancer patients 
express higher IP3R2/IP3R3 levels compared to the adjacent 
non-tumorigenic tissue, which has been related to subsequent 
alterations in metabolic products (123, 124). IP3Rs were shown 
to be critical for the growth-stimulating effects of 17β-estradiol 
(E2) on tumorigenic MCF-7 breast cancer cells (125). E2 applica-
tion exerted both acute and long-term effects on IP3Rs and Ca2+ 
signaling in MCF-7 cells. Acute E2 application triggered IP3R-
mediated Ca2+ release, while prolonged E2 application resulted in 
an upregulation of IP3R3 expression. Further work indicated that 
IP3R3 and Ca2+-dependent K+ channels (BKCa) functioned in a 
concerted manner sustaining breast cancer cell proliferation by 
forming a macromolecular complex (126). Both IP3R3 and BKCa 
were critical for the proliferation of MCF-7 cells. Excitingly, in 
non-tumorigenic MCF-10A cells, IP3R3 and BKCa did not form 
such a complex and their expressions were dispensable for the 
proliferation of these cells (126). IP3Rs have also been implicated 
in the migration of cancer cells, a process associated by an 
epithelial–mesenchymal transition and stimulated upon loss of 
cell–cell contact (127). In disconnected pancreatic ductal adeno-
carcinoma (PDAC) cells, IP3Rs, together with Stim1-containing 
ER–PM junctions, redistributed to the leading edge of individual 
PDAC cells, supporting PDAC cell migration (127). Moreover, 
the selective inhibition of IP3Rs and SOCE lead to reduced cell 
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migration underlying the importance of Ca2+ signaling in this 
process (127). Increased IP3R3 expression and IP3R-derived Ca2+ 
signals have also been shown to correlate with the invasive prop-
erties of glioblastoma cells (128, 129). Inhibition of IP3Rs with 
caffeine inhibited the invasion and migration of glioblastoma 
cells and increased the survival of mice xenografted with glioblas-
toma cells (128). Interestingly, not only inhibition of IP3Rs but 
also stimulation of IP3Rs suppresses glioblastoma cell growth and 
invasion. Indeed, trifluoperazine (TFP), a FDA-approved anti-
psychotic drug, impeded proliferation, invasion, and motility of 
glioblastoma cells in  vitro and in  vivo by eliciting Ca2+ release 
from the ER through IP3R1 and IP3R2 channels, while IP3R3 
channels were dispensable for TFP-induced Ca2+ mobilization. 
TFP-induced Ca2+ rise also depended on the presence of the 
calmodulin subtype 2 (CaM2) protein, which correlates with pre-
vious work revealing TFP as a calmodulin-inhibitory molecule 
by inducing a conformational change in Ca2+-calmodulin (130). 
Hence, it was proposed that TFP by targeting and antagonizing 
CaM2 alleviates CaM2’s inhibitory action on IP3Rs, resulting 
in a potent and irreversible Ca2+ release, responsible for the 
cell growth and invasion restraint of glioblastoma cells (129). 
More recently, IP3R-mediated Ca2+ signaling has been shown 
to be critical for normal T-cell development through repression 
of Sox1, an antagonist of the transcription factor Tcf1, which is 
important for normal T-cell development. In the absence of IP3R 
expression and activity, Notch signaling becomes active in T cells 
in post β-selection thymocytes, resulting in the development of 
aggressive T-cell acute lymphoblastic leukemia (131).
Autophagy in Cancer
Autophagy is a basic catabolic process, existing in all types of 
cells, where it functions mostly in controlling protein turnover 
and sustaining energetic balance (132). In cancer, however, the 
role of autophagy is more complex and can exert different effects 
depending on the stage of tumor progression, tissue origin, 
genetic background, etc. Therefore, autophagy in cancer can serve 
as both a tumor suppressive and a tumor-promoting mechanism 
(133–135).
The essential autophagy protein Beclin 1, encoded by the 
gene BECN1, has been shown to act as a haploinsufficient tumor 
suppressor protein (136). In fact, mice that are haplo-deficient 
for BECN1 develop spontaneous tumors due to an impaired 
basal autophagy and in humans, mutations in BECN1 occur 
in up to 75% of breast, ovarian, and prostate cancers (137). 
Also other autophagy-involved proteins, such as UV radiation 
resistance-associated gene (UVRAG), Atg5, and Atg7, were 
recently described as tumor suppressors (137). These findings 
strongly support an oncosuppressive role of autophagy especially 
at early stages of tumor development. Autophagy contributes to 
the maintenance of cellular homeostasis, largely by degradation 
of protein aggregates and dysfunctional mitochondria but also 
by supplying nucleotides for DNA repair processes (138, 139). 
This further protects cells against proteotoxicity, oxidative stress, 
and genomic instability—the conditions supporting tumor 
development. In some settings, autophagy was also shown to be 
necessary to execute cell death to prevent tumor transformation 
(140). In p53-mediated cell death, expression of the lysosomal 
protein damage-regulated autophagy modulator-1 (DRAM-1), 
responsible for autophagy induction, was critical for apoptosis 
to occur (141). DRAM-1 was also shown to be downregulated in 
a subset of epithelial cancers (141) possibly underlying a similar 
tumor-suppressive function as Beclin 1.
In contrast to this, cancer cells become addicted to autophagy 
at the later stage of tumorigenesis. Studies from Guo et  al. 
(142, 143) revealed that in Kras-driven, genetically engineered 
mouse models of non-small-cell lung cancer (NSCLC), deletion 
of Atg7 caused accumulation of mitochondria, suppression of 
tumor growth and the promotion of tumor cell death. These 
data underscore the role of Atg7, which was required for NSCLC 
growth, survival, and malignancy. Furthermore, systemic genetic 
ablation of Atg7 in mice with established NSCLC, promoted 
tumor regression before damage occurred to the normal tissues 
(144). These findings indicate that tumors can be selectively 
autophagy dependent and that there exists a “therapeutic win-
dow” for autophagy modulation (144). In particular, autophagy 
could compensate metabolic stress by providing bioenergetics 
substrates for the TCA cycle and nucleotides for biosynthetic 
pathways, thereby supporting cancer cell survival (139). In 
Kras-driven NSCLC, autophagy-mediated recycling was able to 
sustain the levels of amino acids and several metabolites during 
starvation. However, further autophagy ablation caused deficien-
cies in mitochondrial substrates. Supplementation of glutamine, 
glutamate, and nucleotides was, therefore, critical to overcome 
autophagy deficiency caused by Atg7 deletion which indicates 
the role of autophagy in starvation survival (139). Autophagy 
can also serve as a tumor pro-survival mechanism in response to 
chemotherapy and other anticancer treatments. It is known that 
the use of anticancer agents, such as 5-fluorouracyl, bortezomib, 
or tamoxifen, results in elevated autophagy, which counteracts 
cell death induction and decreases therapy efficiency (145). 
Recently, it has been described that verapamil, an L-type calcium 
channel blocker, can induce a cytotoxic effect and autophagy in 
colon cancer cells. Cell death in these cells was further increased 
when verapamil treatment was accompanied by chloroquine, 
an autophagy inhibitor, or when autophagy was ablated by Atg5 
and Atg7 deletion (146). Usage of chloroquine and hydroxychlo-
roquine is a common strategy for autophagy inhibition and, 
therefore, the enhancement of anticancer therapy effectiveness 
(147). Recent studies, however, have shown that chloroquine 
can exert anticancer effects independently of autophagy (148). 
In fact, chloroquine acted by reducing intratumoral hypoxia and 
metastasis, specifically normalizing tumor vessels by a mecha-
nism involving NOTCH-1. Nevertheless, the use of autophagy 
inhibitors, as well as genetic tools to abort autophagy, strongly 
support the hypothesis of tumor-promoting effects of autophagy 
at the later stages of tumor development.
As discussed above, autophagy is most likely playing a 
tumor-suppressive role at early steps of tumor development, 
while it tends to function as a tumor-promoting mechanism in 
established tumors. This division, however, is not always clear as 
the role of autophagy in cancer can also depend on other factors 
such as the genetic background of a particular tumor. Recent 
studies revealed that in a humanized genetically modified mouse 
model of PDAC, deletion of autophagy genes Atg5 and Atg7 can 
FiGURe 2 | Endoplasmic reticulum (ER)–mitochondria Ca2+ transfer regulates apoptosis and autophagy in cancer. In all panels, the black arrows mirror the basal 
cellular mechanisms while the red arrows indicate modulation of the pathways by the listed chemical compounds or genetic modifications. (A) IP3Rs are engaged in 
autophagy and cell death regulation via the ER–mitochondrial Ca2+ flux. Ca2+ transferred to the mitochondria ensures proper tricarboxylic acid (TCA) function and, 
therefore, adequate bioenergetics and biosynthesis processes suppressing autophagy. Inhibition of IP3Rs by Xestospongin B (XeB) or its genetic knockdown (KD) 
dampens ER–mitochondrial Ca2+ transfer, which inhibits the TCA cycle and ATP production. As a consequence, autophagy is increased, but this is not sufficient for 
the survival of cancer cells, which undergo mitotic catastrophe. In addition to this, inhibition of IP3Rs by 2APB or Xestospongin C (XeC) also leads to impeded 
ER–mitochondrial Ca2+ fueling, and subsequently to further autophagy-dependent cancer cell death. (B) Fueling mitochondria with Ca2+ can be modulated by 
several oncogenes/tumor suppressors [promyelocytic leukemia protein (PML), PTEN, PKB/Akt]. In cancer cells lacking PML (KO, knockout), mitochondrial Ca2+ 
transfer is impeded resulting in downregulation of TCA cycle, stimulation of autophagy, and of cell growth. (C) Mitochondrial Ca2+ transfer can also be indirectly 
controlled by mitochondrial F0F1 ATPase. Its inhibition by resveratrol (RSV) impairs sarco/endoplasmic reticulum Ca2+ ATPases (SERCA) function, thereby increasing 
the net Ca2+ flux from the ER and promoting mitochondrial Ca2+ overload, eventually leading to apoptosis. In addition, SERCA is negatively regulated by 
thioreductase TMX1. Cancer cells having low levels of TMX1, exert high SERCA activity, which correlates with decreased ER–mitochondrial Ca2+ transfer. 
Consequently, the TCA cycle is limited and cells switch to aerobic glycolysis (Warburg effect).
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play different roles according to the status of p53 (149). In mice 
possessing an oncogenic allele of Kras, ablation of Atg5 and Atg7 
prevented further tumor development. However, in mice with 
mutated Kras and additionally lacking p53, blockage of autophagy 
significantly accelerated formation of tumor lesions (149, 150). 
This and other examples (151) indicate that the role of autophagy 
strongly depends on the tumor context and this should be consid-
ered while designing autophagy modulation-based therapies. For 
a further discussion on the role of autophagy in cancer, we refer 
to more detailed reviews (152–155).
iP3Rs AND AUTOPHAGY CONTROL:  
A ROLe iN CANCeR?
Autophagy Contribution to Modulation of 
Cancer Cell Death induced by iP3R 
inhibition
Recently, it was shown that cancer cells may be addicted to basal 
IP3R activity and its critical role in feeding mitochondria with 
Ca2+, a regulator of the activity of several TCA cycle enzymes. 
Similarly to non-tumorigenic cells, in tumorigenic cells IP3R 
inhibition or KD resulted in an increased autophagic flux (156). 
However, while this was sufficient to sustain cell survival in non-
tumorigenic cells, the increase in autophagy was not sufficient 
for the survival of cancer cells. Thus, pharmacological inhibition 
using xestospongin B or genetic KD of IP3Rs in cancer cells 
resulted in cancer cell death (156) (Figure 2A). Mitochondrial 
Ca2+ and its positive effect on the TCA cycle does not only serve 
to support ATP synthesis but also to support several anabolic 
pathways that use mitochondrial TCA cycle intermediates in 
their biosynthetic pathway (157). In non-tumorigenic cells, the 
lack of ER–mitochondrial Ca2+ transfers due to IP3R inhibition 
dampened cell cycle progression, thereby arresting cells at the 
G1/S checkpoint. Indeed, adequate ATP production is an integral 
part of the G1/S checkpoint and a surge in ATP production is 
needed for cells to progress from the G1 phase to the S phase 
via a mechanism that involves cyclin E upregulation (158). This 
surge in ATP output is achieved by mitochondrial hyperfusion 
at that stage of the cell cycle (159). In cells experiencing blunted 
ER–mitochondrial Ca2+ transfer (like upon IP3R inhibition), ATP 
output would be impaired and AMPK can be activated. One of 
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the outcomes of AMPK activation besides autophagy induction 
is the activation of p53/p21, which downregulates cyclin E levels. 
As a consequence, cells cannot proceed from the G1 to S phase 
and are arrested (157). However, one feature of cancer cells is 
their uncontrolled proliferation. In fact, many cancer cells have 
mutations in p53 or display dysregulated cell cycle control (160). 
In that sense, these cancer cells become addicted to their mito-
chondrial metabolism to produce mitochondrial intermediates 
that are used for synthesis of lipids, nucleotides, and proteins, 
supporting the survival of the dividing cells. Cancer cells exposed 
to IP3R inhibitors will, thus, not slow down their cell cycling. As 
a consequence, these cells will continue to divide irrespective of 
the surge in mitochondrial ATP output and the availability of 
mitochondrial intermediates needed for biosynthesis upon cell 
division. Without sufficient lipids and nucleotides, the daughter 
cells will not be able to survive. Hence, IP3R inhibition caused a 
mitotic catastrophe in cancer cells. Consequently, cell death in 
these cells could be overcome by the addition of mitochondrial 
substrates, such as pyruvate, to the growth medium or by slow-
ing down cell cycle progression (156). Yet, autophagy was not 
involved in the cell death process, as KD of essential autophagy 
genes did not modulate IP3R inhibition-induced cell death. This 
indicates that cell death did not occur via autophagic cell death 
and also that autophagy activation could not support survival of 
the cells.
In contrast to these findings, another study revealed an 
important role for autophagic cell death in breast cancer cells 
exposed to IP3R inhibition (123) (Figure  2A). Tumorigenic 
breast cancer cells were sensitive to treatment with the non-
specific IP3R inhibitors, 2-APB or xestospongin C, while non-
tumorigenic breast cancer cells were resistant to this treatment. 
However, these compounds, as well as their derivatives, can 
indirectly cause depletion of the ER Ca2+ stores by inhibiting 
other Ca2+ transporters or by stimulating Ca2+ leakage out of 
the ER (161–164). Nevertheless, similar findings were obtained 
by genetically knocking down IP3R2 or IP3R3, which appear to 
be upregulated in tumorigenic versus non-tumorigenic breast 
cancer cell lines. Inhibition of IP3Rs in the tumorigenic cells 
resulted in excessive autophagy activation, which could be 
attributed to a decrease in ATP production (and thus activation 
of AMPK), an upregulation of Atg5 and an increase in ROS 
production. In these cells, excessive autophagy was responsible 
for cell death, as inhibition of autophagy either at the level of 
the Vps34 complex formation using 3-methyladenine or at the 
level of lysosomal degradation by Bafilomycin A1 protected cells 
against cell death induced by IP3R inhibition or IP3R KD (123). 
These in vitro findings were also translated to in vivo xenografted 
breast tumor models. Interestingly, the increase in IP3R2/IP3R3 
expression was not only found in breast cancer cell lines but 
also found in patient samples consisting of breast tumor tissue 
compared to adjacent non-tumorous tissue. Moreover, IP3R2/
IP3R3 upregulation in breast tumors correlated with an increase 
in lipoproteins and several metabolites (such as lactate, alanine, 
and lysine) in the serum of these patients compared to breast 
cancer patients with low IP3R2/IP3R3 levels or healthy controls 
(124). Unfortunately, no autophagic markers were analyzed in 
these samples.
Downregulation of Autophagy and 
increased Apoptosis Susceptibility in 
Response to iP3R Modulation by Tumor 
Suppressors
As previously discussed, IP3Rs suppress basal autophagy by pro-
moting mitochondrial ATP production. In addition to this, IP3Rs 
control the susceptibility of cells toward toxic, pro-apoptotic 
stimuli. By promoting Ca2+ transfer into the mitochondria, IP3Rs 
participate in mitochondrial Ca2+ overload, a critical factor in the 
opening of the mitochondrial permeability transition pore and 
subsequent apoptosis. In fact, mitochondrial Ca2+ overload has 
been shown to be a critical component of several pro-apoptotic 
stimuli, including chemotherapeutic drugs (165). These stimuli 
can trigger Ca2+ release from the ER. In addition, these com-
pounds can trigger ER Ca2+ overload by activating SERCA in a 
p53-dependent manner (120). As a consequence, such cells will 
display an increased likelihood for mitochondrial Ca2+ accu-
mulation and thus cell death. In fact, cancer cells lacking p53 or 
expressing loss-of-function p53 mutants are resistant to chemo-
therapeutic drugs in part due to their lack of mitochondrial Ca2+ 
overload, as these cells can be re-sensitized to chemotherapeutics 
by overexpressing MCU (120, 166). In particular, the IP3R3 iso-
form appears to participate in pro-apoptotic Ca2+ transfer into the 
mitochondria due to its presence in the MAMs (167). Moreover, 
IP3R3 activity in the MAMs is subjected to functional modulation 
by survival/oncogenes and tumor suppressors (Figure 2B). IP3R3 
is phosphorylated by PKB/Akt, suppressing ER–mitochondrial 
Ca2+ flux and promoting apoptosis resistance (112). PKB/Akt-
mediated phosphorylation of IP3R3 is counteracted by PTEN, 
which dephosphorylates IP3R3 particularly at the MAM fraction 
and, therefore, stimulates pro-apoptotic Ca2+ transfer from the 
ER into the mitochondria (117). Another regulator of PKB/Akt-
dependent phosphorylation of IP3R3 is the tumor suppressor 
promyelocytic leukemia protein (PML), which also resides at the 
MAMs, where it recruits PP2A, which suppresses PKB/Akt activ-
ity (168). In addition to this, downregulation of IP3R3-protein 
levels has been implicated in cancer transformation and cell death 
resistance of isogenic cell pairs, in which an oncogenic mutant 
Ras allele was expressed (118).
More recently, further insights into the contribution of IP3R 
modulation in the tumor suppressive function of PML have 
been revealed (168, 169). PML was recruited at the MAMs in 
a p53-dependent manner supporting efficient ER–mitochondrial 
Ca2+ transfer (Figure  2B). As a consequence, cells expressing 
the tumor suppressor PML were susceptible to engage apoptosis 
upon cell stress or damage and to maintain an adequate produc-
tion of ATP, preventing the growth of damaged or malignant 
cells. These conditions dampened AMPK activity and, thus, 
result in a regular basal autophagic flux. The combination 
of adequate apoptosis sensitivity and regular autophagy flux 
allows for a normal and balanced cell growth. However, in cells 
lacking PML, ER–mitochondrial Ca2+ transfer was suppressed, 
resulting in excessive apoptosis resistance and an upregulation 
of basal autophagy due to suppressed ATP production followed 
by AMPK activation and thus increased ULK1 activity. The 
increase in autophagy upon PML deletion in cells could be 
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attributed to the decreased mitochondrial Ca2+ signaling, since 
overexpression of MCU in these cells could suppress basal 
autophagic flux (168). Moreover, PML-deficient cells displayed a 
growth advantage compared to PML-proficient cells, particularly 
in stress conditions such as nutrient starvation that engage the 
autophagy pathway. Interestingly, PML-deficient cells could be 
sensitized to chemotherapeutic drugs such as 5-fluorouracil by 
co-administration of chloroquine, an autophagy inhibitor that 
acts at the level of the lysosomal proteolysis. Moreover, in some 
promyelocytic leukemia cells, PML became fused to retinoic 
acid receptor α (RARα), abrogating wild-type endogenous PML 
function and causing neoplastic transformation. This oncogenic 
PML fusion was degraded by stimulating the proteasome using 
arsenic trioxide. Treatment of cells expressing oncogenic PML 
fusion protein with this drug not only resulted in PML-RARα 
degradation but also rescued wild-type PML levels, which was 
then present in the MAMs and able to promote ER–mitochon-
drial Ca2+ transfer (168).
Another tumor suppressor actively involved in autophagy 
regulation is Beclin 1. Interestingly, a target of Beclin 1 is the 
IP3R, which becomes sensitized upon Beclin 1 binding, a process 
enhanced during nutrient starvation (58). Thus, cancer cells, 
commonly deficient in Beclin 1, will not only be able to form less 
complexes with the lipid kinase Vps34 but also with the IP3Rs, 
what may lead to decreased autophagy. However, at this point, it 
is not clear how decreased IP3R/Beclin 1-complex formation con-
tributes to basal autophagy and how this impacts tumorigenesis.
indirect impact of iP3R on Autophagy in 
Cancer Cells: effects of eR Ca2+ 
Modulation
Resveratrol, a natural polyphenol, is well known to induce cancer 
cell death by engaging autophagy induction via different mecha-
nisms (82, 170–172), including the modulation of Ca2+ signaling 
(173). More recently, further insights into RSV-induced cancer 
cell death via Ca2+ signaling have been obtained (84). In particu-
lar, cancer cells can display increased ER–mitochondrial contact 
sites, potentially to facilitate the transfer of basal Ca2+ signals to 
accommodate their increased need for mitochondrial TCA cycle 
activity, which also provides substrates for several biosynthetic 
pathways. Exposing cancer cells to RSV resulted in a rapid 
depletion of the ER Ca2+ stores. The underlying mechanisms 
appeared to involve the direct inhibition of the mitochondrial 
F0F1-type ATP synthase, resulting in a rapid drop in ATP levels, 
in particular at the ER–mitochondrial contact sites (Figure 2C). 
SERCA activity is thereby impaired, leading to a net increase of 
Ca2+ delivery to the mitochondria, as for a given IP3-induced 
Ca2+ release less Ca2+ will be pumped back in the ER. Thus, 
mitochondrial Ca2+ levels will increase, thereby promoting cell 
death. The concept of SERCA modulating ER–mitochondrial 
Ca2+ transfer in cell death and tumor biology has been nicely 
illustrated in a recent study of Raturi et  al. (174). It has been 
shown that SERCA activity was dynamically regulated at the 
ER–mitochondrial contact sites by different factors, including 
palmitoylated calnexin, which positively regulated SERCA, and 
the thioreductase TMX1, which negatively regulated SERCA. 
In normal cells, TMX1 levels are high, thereby suppressing 
SERCA activity and thus promoting ER–mitochondrial Ca2+ 
transfer. This supports mitochondrial metabolism on the one 
hand and adequate apoptotic susceptibility on the other hand. 
Interestingly, many tumors display low TMX1 levels, which results 
in increased SERCA activity, particularly at the MAMs, leading to 
dampened ER–mitochondrial Ca2+ transfer (Figure 2C). This was 
proposed to contribute to the Warburg effect and increased gly-
colysis, as the activity of TCA cycle enzymes became suppressed, 
while the need for glucose metabolism remained high to sustain 
cell growth and proliferation (174, 175). Nevertheless, it is pos-
sible that these findings relate to concepts identified for PML at 
the ER–mitochondrial interface. Indeed, tumors with low TMX1 
levels may display increased autophagy and decreased apoptosis 
susceptibility due to suppressed ER–mitochondrial Ca2+ fluxes. 
However, further work is needed to reconcile these concepts.
iP3R-Regulated Autophagy As a Protection 
against Natural Killer (NK)-induced Cancer 
Cell Death
Recently, ITPR1, the gene encoding IP3R1, has been implicated 
as a major resistance mechanism of renal carcinoma cells against 
the lytic action of NK cells by activating autophagy (176–178). 
Many renal carcinoma cells are characterized by a dysfunctional 
von Hippel–Lindau gene (pVHL), which encodes a protein that 
has many functions, including targeting the family of hypoxia-
inducible factor transcription factors for degradation by the 
proteasome. Thus, in cells lacking pVHL, HIF1α/HIF2α become 
stabilized. Currently, an emerging concept in anticancer therapies 
is the use of NK  cells. Tumor cells contain several resistance 
factors against NK-induced cancer cell killing, including stabi-
lized HIF2α. Strikingly, ITPR1 appeared to be one of the most 
important target genes of HIF2α in a renal carcinoma cell line 
with dysfunctional pVHL gene and it conferred resistance against 
NK-induced lysis. In particular, renal carcinoma cells upregulated 
pro-survival autophagy in a HIF2α/IP3R1-dependent manner in 
response to NK treatment, while cells in which IP3R1 was knocked 
down failed to stimulate autophagy and became susceptible to 
NK-induced lysis. The IP3R1-dependent induction of autophagy 
protected the carcinoma cells against the deleterious action of 
NK cells by degrading the lytic granzyme B. In renal carcinoma 
cells with functional pVHL, HIF2α levels are very low due to its 
targeting to the proteasome, thus failing to upregulate ITPR1 
expression and abrogating autophagy induction as resistance 
mechanism against NK cells and the lytic action of granzyme B. 
Thus, antagonizing IP3R function in renal carcinoma cells lacking 
functional pVHL may provide a manner to sensitize these cells to 
lysis by NK cells by counteracting the induction of autophagy as a 
resistance mechanism. Furthermore, also NK cells by themselves 
require functional autophagy for maturation and survival (179). 
Upon deletion of Atg5, NK cells accumulated damaged mitochon-
dria, which lead to their death due to excessive ROS production. 
Furthermore, silencing Atg7 and the resulting disruption of the 
interaction between Atg7 and phosphorylated forkhead box O1 
(FOXO1) prevented autophagy and contributed to incomplete 
maturation of NK cells (179).
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CONCLUSiON
IP3Rs play a critical role in autophagy due to their localization at 
the ER and the ER–mitochondrial contact sites and the result-
ing Ca2+-signaling regulation. On the one hand, they suppress 
autophagy by continuously sustaining the mitochondria with 
Ca2+, needed for mitochondrial metabolism and energy pro-
duction. On the other hand, they participate in the increased 
autophagic flux induced upon cellular stress, including nutri-
ent starvation, chemical mTOR inhibition, or RSV treatment, 
by providing cytosolic Ca2+ that is needed to drive autophagic 
flux. Given autophagy’s critical role in tumor development and 
progression, it is not surprising that IP3R function can affect these 
processes through autophagy modulation. Cancer cells appear to 
be addicted to IP3R-mediated Ca2+ release to sustain their mito-
chondrial metabolism and related anabolic pathways. Cancer 
cells exposed to IP3R inhibition can undergo cell death, which in 
some cases could be due to excessive autophagy induction, while 
in other cases cell death could be the result of an uncontrolled cell 
proliferation and thus be due to mitotic catastrophe. Also, IP3Rs 
are modulated by tumor suppressors, such as PML, as part of a 
homeostatic program to support normal cell growth by balancing 
adequate apoptosis susceptibility and regulated autophagy flux. 
However, loss of these tumor suppressors results in dampened 
IP3R function and thus defective ER–mitochondrial Ca2+ transfer. 
As a consequence, cells become resistant to cell death inducers, 
including genotoxic stress and cell damage, by a combination 
of increased apoptosis resistance and an increased autophagy 
flux serving as a pro-survival function. This phenomenon will 
contribute to neoplastic transformation and tumorigenesis. The 
role of IP3Rs in autophagy seem also to be exploited by renal car-
cinoma cells with dysfunctional pVHL, which induce autophagy 
in a HIF2α/IP3R-dependent manner as a resistance mechanism 
that protects these cancers against NK-induced killing. Finally, 
it should be noted that IP3R function and the net IP3R-mediated 
Ca2+ delivery into the mitochondria is dependent on the activity 
of SERCA, which is also present in the MAMs. Thus, SERCA 
modulation at the ER–mitochondrial contact sites will affect 
the net Ca2+ transfer into the mitochondria and, thus, ultimately 
affect the Ca2+-dependent mitochondrial functions, such as bio-
energetics, autophagy, and apoptosis. SERCA inhibition in the 
MAMs will increase mitochondrial Ca2+ accumulation, which 
will drive the mitochondrial metabolism and bioenergetic output 
and thus suppress autophagy. In cancer cells, de-inhibition of 
SERCA at the ER–mitochondrial contact sites can be part of the 
Warburg effect but also of the increase in basal autophagy that 
could promote neoplastic behavior by promoting cell survival and 
excessively protecting cancer cells against cell stress. Overall, IP3Rs 
impact several cancer hallmarks through autophagy modulation.
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